Brind.

Goldman Sachs initiated coverage of Crinetics Pharmaceuticals with a Hold rating on July 16, 2025.

1 report, 1 independent Updated Jul 16

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Goldman Sachs Crinetics Pharmaceuticals

Keep exploring

The entities involved

Goldman Sachs
American investment bank
- US-Iran truce aims to reopen Strait of Hormuz amid global monetary policy shifts and oil price drops.Mon 17:37
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
Crinetics Pharmaceuticals
company in San Diego, United States

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Jul 16Insider MonkeyCrinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best oversold NASDAQ stocks to buy now. In a report rel